Based on the protein signatures identified, patients with more diffuse tumor immune infiltration are more likely to benefit from targeting PD-L1/PD-1, IDO1 and/or Tim-3, while tumors with focal immune infiltration patterns showed increased presence of CD163+ macrophages and a preliminary worse outcome. The gene discussed is IDO1; the disease is neoplasm.